As the world prepares to commemorate World Tuberculosis (TB) Day, Faberco Life Sciences Incorporated proudly announces a breakthrough in the Philippines’ fight against drug-resistant tuberculosis (DR-TB). The Health Technology Assessment (HTA) Council issued a positive recommendation for the public financing of Pretomanid 200 mg tablet, paving the way for its inclusion in national treatment programs through the Department of Health (DOH) and/or PhilHealth.
Faberco Life Sciences Inc., as the marketing authorization holder for Pretomanid, has worked in close collaboration with the National TB Program to support the implementation of the BPaL Operational Research Program. This partnership has been instrumental in aligning clinical protocols, ensuring regulatory compliance, and facilitating access to the BPaL regimen for eligible patients.
This milestone is further validated by the DOH Department Circular No. 2025-0341, which officially approves the inclusion of Pretomanid in the Philippine National Drug Formulary (PNDF).
As stated in the circular, Pretomanid is recognized as part of a combination regimen with bedaquiline and linezolid (with or without moxifloxacin) for the treatment of multidrug-resistant (MDR) or rifampicin-resistant TB (RR-TB) in patients aged 14 years and older. Pretomanid represents a new generation of DR-TB treatment regimen—shorter, safer, and more effective than traditional regimens, which are often prolonged, toxic, and difficult to complete. The HTA Council’s recommendation and the DOH’s formal endorsement underscore the drug’s clinical value and its potential to transform patient outcomes.
In partnership with Viatris, Faberco Life Sciences has taken a leading role in introducing Pretomanid to the Philippine market. This collaboration reflects Faberco’s commitment to addressing unmet medical needs and advancing health equity by making innovative treatments accessible to Filipino patients.
With this progress, Pretomanid is now on the path to being integrated into government-supported TB treatment programs, offering renewed hope to patients, healthcare providers, and public health stakeholders. FLSI remains steadfast in its mission to support collaborative action, innovation, and the eradication of TB in the Philippines.
Reference : HTA Philippines